A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors

被引:161
作者
Collett, K
Stefansson, IM
Eide, J
Braaten, A
Wang, H
Eide, GE
Thoresen, SO
Foulkes, WD
Akslen, LA
机构
[1] Harvard Univ, Sch Med, Childrens Hosp,Vasc Biol Program, Folkman Lab,Karp Family Res Labs 12 125, Boston, MA 02115 USA
[2] Haukeland Hosp, Dept Pathol, Gade Inst, Oslo, Norway
[3] Haukeland Hosp, Dept Radiol, Oslo, Norway
[4] Haukeland Hosp, Clin Res Ctr, Oslo, Norway
[5] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway
[6] Canc Registry Norway, Oslo, Norway
[7] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
[8] McGill Univ, Dept Med, Montreal, PQ, Canada
关键词
D O I
10.1158/1055-9965.EPI-04-0394
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interval breast cancer reduce the effectiveness of mammography screening programs. We studied 95 interval cancers, diagnosed during 1996 to 2001 as part of the population-based Norwegian Breast Cancer Screening Program. These cases were matched on size (+/- 2.0 mm) to 95 screen-detected breast cancers, and the tumors were compared by immunohistochemical methods using tissue microarrays. Patients with interval cancers were more likely to be younger [odds ratio (OR), 4.7; P = 0.0001], to have dense breasts (OR, 3.4; P = 0.004), and to have estrogen receptor-negative tumors (OR, 2.6, P = 0.01), and p53 expression was more frequent (OR, 4.0; P = 0.001). Notably, interval cancers were more likely to have a basal epithelial phenotype, in that expression of cytokeratin 5/6 (OR, 2.3; P = 0.04) and P-cadherin (OR, 2.5; P = 0.04) was more frequent in interval cases than in size-matched, screen-detected tumors. In a logistic regression model, p53 expression, age, and breast density were independent predictors of interval cancers. Our data suggest that breast cancers with a basal epithelial phenotype are more likely than nonbasal breast cancers to present between regular mammograms.
引用
收藏
页码:1108 / 1112
页数:5
相关论文
共 49 条
[1]  
Anttinen J, 2003, ANTICANCER RES, V23, P4213
[2]   TP53 and breast cancer [J].
Borresen-Dale, AL .
HUMAN MUTATION, 2003, 21 (03) :292-300
[3]  
Brekelmans CT, 1996, CANCER, V78, P1220, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1220::AID-CNCR8>3.0.CO
[4]  
2-D
[5]   Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk [J].
Brekelmans, CTM ;
Seynaeve, C ;
Bartels, CCM ;
Tilanus-Linthorst, MMA ;
Meijers-Heijboer, EJ ;
Crepin, CMG ;
van Geel, AN ;
Menke, M ;
Verhoog, LC ;
van den Ouweland, A ;
Obdeijn, IM ;
Klijn, JGM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :924-930
[6]  
Breslow N E, 1980, IARC Sci Publ, P5
[7]   Screening interval breast cancers: Mammographic features and prognostic factors [J].
Burrell, HC ;
Sibbering, DM ;
Wilson, ARM ;
Pinder, SE ;
Evans, AJ ;
Yeoman, LJ ;
Elston, CW ;
Ellis, IO ;
Blamey, RW ;
Robertson, JFR .
RADIOLOGY, 1996, 199 (03) :811-817
[8]   Molecular classification of breast carcinomas using tissue microarrays [J].
Callagy, G ;
Cattaneo, E ;
Daigo, Y ;
Happerfield, L ;
Bobrow, LG ;
Pharoah, PDP ;
Caldas, C .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2003, 12 (01) :27-34
[9]   Validation of tissue microarray technology in breast carcinoma [J].
Camp, RL ;
Charette, LA ;
Rimm, DL .
LABORATORY INVESTIGATION, 2000, 80 (12) :1943-1949
[10]   A study of interval breast cancer within the NHS breast screening programme [J].
Cowan, WK ;
Angus, B ;
Gray, JC ;
Lunt, LG ;
Al-Tamimi, SR .
JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (02) :140-146